Tag: common shares

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies¹, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- (TSX: PIC.A; PIC.PR.A) Premium Income Corporation (the “Fund”) announces results of operations for the six months ended April 30, 2025. Decrease in net assets attributable to holders of Class A shares amounted to $5.7 million or $0.38 per Class A share. Net assets attributable to holders of Class A shares as at April 30, 2025 were $81.2 million or $5.12 per Class A share. Cash distributions of $0.64 per Preferred share and $0.48 per Class A share were paid during the period.

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Cboe Canada: MLC) (“Mount Logan,” “our,” “we,” or the “Company”) announced that at the annual meeting of shareholders held on June 18, 2025 (the “Meeting”), each of the six nominees listed in the management information circular dated May 13, 2025 (the “Circular”) were elected as directors of the Company. A total of 31,979,130 votes or 55.78% of Mount Logan’s issued and outstanding common shares were voted in connection with the Meeting. The detailed results of the vote for each of the six elected directors are set out below.

MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is undertaking a rights offering (the “Rights Offering”). The Company will be offering a maximum of 353,409,888 rights (the “Rights”) to holders (the “Shareholders”) of its common shares (the “Shares”) as at the close of business on the record date of June 25, 2025 (the “Record Date”) on the basis of one (1) Right for each one (1) Share held. Each one (1) Right will entitle the holder to subscribe for one Share (each, a “Rights Share”) at the subscription price of $0.0825 per Rights Share.

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.